Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP General Counsel and Secret | August 19, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,373 |
Ending reported balance
After 2026-08-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-19 · Exercise / conversion · Acquired 12,282 · Balance 45,392 Row 2 · 2026-08-19 · Tax withholding · Disposed 9,019 · Balance 36,373 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $381.92 · Expires 2026-12-16 | Direct | 12,283 |
Reported balance
After 2026-08-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-19 · Exercise / conversion · Disposed 12,282 · Balance 12,283 F1: The stock option award vested in four equal annual installments, commencing one year after the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy 2024 GRAT | 3,402 |
Reported balance
Holding disclosure · report date 2026-08-19 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,402 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT | 5,407 |
Reported balance
Holding disclosure · report date 2026-08-19 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,407 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 413 |
Reported balance
Holding disclosure · report date 2026-08-19 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 413 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option award vested in four equal annual installments, commencing one year after the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Merck & Co., Inc.
Report date November 17, 2003 · Filed November 18, 2003
Section 16 reporting ended · disclosed 2003-11-18. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 21, 2026 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,282 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001238303-26-000002 · edgardoc.xml · derivative · entry 6 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,283 Underlying: Common Stock · 12,282 shares Expires 2026-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 9,019 | $830.15 | $7,487,122.85 |
DisclosureSEC source: 0001238303-26-000002 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,373 Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 12,282 | $381.92 | $4,690,741.44 |
DisclosureSEC source: 0001238303-26-000002 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,396 | $712.94 | $995,264.24 |
DisclosureSEC source: 0001238303-25-000007 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,517 Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,210 | $0.00 Strike: $726.71 | $0.00 |
DisclosureSEC source: 0001238303-25-000007 · edgardoc.xml · derivative · entry 6 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,210 Underlying: Common Stock · 12,210 shares Expires 2035-12-05 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,476 | $0.00 | $0.00 |
DisclosureSEC source: 0001238303-25-000007 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,913 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 5, 2027 and 50% on December 5, 2029. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 14,450 | $0.00 Strike: $555.67 | $0.00 |
DisclosureSEC source: 0001238303-25-000005 · edgardoc.xml · derivative · entry 6 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,450 shares Expires 2025-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 12,686 | $736.77 | $9,346,664.22 |
DisclosureSEC source: 0001238303-25-000005 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,839 Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 14,450 | $555.67 | $8,029,431.50 |
DisclosureSEC source: 0001238303-25-000005 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 702 | $730.81 | $513,028.62 |
DisclosureSEC source: 0001883850-24-000062 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,075 Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 492 | $787.00 | $387,204.00 |
DisclosureSEC source: 0001968202-24-000135 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,777 Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,981 | $0.00 Strike: $771.64 | $0.00 |
DisclosureSEC source: 0001968202-24-000135 · edgardoc.xml · derivative · entry 5 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,981 Underlying: Common Stock · 8,981 shares Expires 2034-12-06 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-24-000135 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,269 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 6, 2026 and 50% on December 6, 2028. Read SEC document |
| July 11, 2024 Filed Jul 12, 2024 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,866 | $1,088.95 | $2,031,980.70 |
DisclosureSEC source: 0001968202-24-000107 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,937 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2024. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 20:39 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 14,450 | $0.00 Strike: $555.67 | $0.00 |
DisclosureSEC source: 0001883850-24-000036 · edgardoc.xml · derivative · entry 4 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,450 Underlying: Common Stock · 14,450 shares Expires 2025-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 20:39 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 11,084 | $1,060.13 | $11,750,480.92 |
DisclosureSEC source: 0001883850-24-000036 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,803 Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 20:39 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 14,450 | $555.67 | $8,029,431.50 |
DisclosureSEC source: 0001883850-24-000036 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-24-000032 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Indirect · 2022 GRAT Disclosed balance after: 0 Read SEC document |
| May 21, 2024 Filed May 22, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,865 | $994.90 | $1,855,488.50 |
DisclosureSEC source: 0001968202-24-000096 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,678 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2024. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $990.00 | $990,000.00 |
DisclosureSEC source: 0001968202-24-000080 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,543 Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $967.65 | $967,650.00 |
DisclosureSEC source: 0001968202-24-000073 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,543 Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $950.00 | $950,000.00 |
DisclosureSEC source: 0001968202-24-000058 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,543 Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $399.66 | $0.00 |
DisclosureSEC source: 0001883850-24-000006 · edgardoc.xml · derivative · entry 5 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 24,493 | $912.30 | $22,344,963.90 |
DisclosureSEC source: 0001883850-24-000006 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,543 Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 34,000 | $399.66 | $13,588,440.00 |
DisclosureSEC source: 0001883850-24-000006 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 669 | $844.09 | $564,696.21 |
DisclosureSEC source: 0001968202-23-000052 · edgardoc.xml · nonDerivative · entry 3 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,036 Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,649 | $0.00 Strike: $843.79 | $0.00 |
DisclosureSEC source: 0001968202-23-000052 · edgardoc.xml · derivative · entry 6 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,649 Underlying: Common Stock · 7,649 shares Expires 2033-12-08 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-23-000052 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,705 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2025 and 50% on December 8, 2027. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 852 | $843.79 | $718,909.08 |
DisclosureSEC source: 0001968202-23-000052 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,572 Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 20:39 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $270.43 | $0.00 |
DisclosureSEC source: 0001883850-23-000061 · edgardoc.xml · derivative · entry 5 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2023-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 20:39 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 6,742 | $801.59 | $5,404,319.78 |
DisclosureSEC source: 0001883850-23-000061 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,471 Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 20:39 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 10,000 | $270.43 | $2,704,300.00 |
DisclosureSEC source: 0001883850-23-000061 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-23-000002 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 GRAT Disclosed balance after: 0 Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,159 | $0.00 Strike: $726.53 | $0.00 |
DisclosureSEC source: 0001883850-22-000133 · edgardoc.xml · derivative · entry 5 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,159 Underlying: Common Stock · 10,159 shares Expires 2032-12-16 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,752 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000133 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,110 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 16, 2024 and 50% on December 16, 2026. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 492 | $753.28 | $370,613.76 |
DisclosureSEC source: 0001883850-22-000122 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,358 Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 20:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $270.43 | $0.00 |
DisclosureSEC source: 0001883850-22-000067 · edgardoc.xml · derivative · entry 6 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 30,000 shares Expires 2023-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 20:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 20,730 | $730.96 | $15,152,800.80 |
DisclosureSEC source: 0001883850-22-000067 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,850 Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 20:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 30,000 | $270.43 | $8,112,900.00 |
DisclosureSEC source: 0001883850-22-000067 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,114 | $721.10 | $3,687,705.40 |
DisclosureSEC source: 0001708138-22-000040 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,900 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 5,114 shares of Company stock on April 7, 2022 at prices ranging from $721.10 to $721.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 7, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 15 | $701.82 | $10,527.30 |
DisclosureSEC source: 0001708138-22-000033 · edgardoc.xml · nonDerivative · entry 15 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,014 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 124 | $698.26 | $86,584.24 |
DisclosureSEC source: 0001708138-22-000033 · edgardoc.xml · nonDerivative · entry 14 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,029 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 64 | $697.35 | $44,630.40 |
DisclosureSEC source: 0001708138-22-000033 · edgardoc.xml · nonDerivative · entry 13 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,153 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 254 | $696.54 | $176,921.16 |
DisclosureSEC source: 0001708138-22-000033 · edgardoc.xml · nonDerivative · entry 12 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,217 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 254 shares of Company stock on April 1, 2022 at prices ranging from $696.12 to $696.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 305 | $695.36 | $212,084.80 |
DisclosureSEC source: 0001708138-22-000033 · edgardoc.xml · nonDerivative · entry 11 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,471 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 305 shares of Company stock on April 1, 2022 at prices ranging from $695.01 to $695.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 259 | $694.56 | $179,891.04 |
DisclosureSEC source: 0001708138-22-000033 · edgardoc.xml · nonDerivative · entry 10 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,776 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 259 shares of Company stock on April 1, 2022 at prices ranging from $694.15 to $694.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 567 | $693.92 | $393,452.64 |
DisclosureSEC source: 0001708138-22-000033 · edgardoc.xml · nonDerivative · entry 9 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,035 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 567 shares of Company stock on April 1, 2022 at prices ranging from $693.62 to $693.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 195 | $692.54 | $135,045.30 |
DisclosureSEC source: 0001708138-22-000033 · edgardoc.xml · nonDerivative · entry 8 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,602 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 195 shares of Company stock on April 1, 2022 at prices ranging from $692.10 to $692.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 641 | $691.44 | $443,213.04 |
DisclosureSEC source: 0001708138-22-000033 · edgardoc.xml · nonDerivative · entry 7 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,797 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 641 shares of Company stock on April 1, 2022 at prices ranging from $691.07 to $691.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 250 | $690.51 | $172,627.50 |
DisclosureSEC source: 0001708138-22-000033 · edgardoc.xml · nonDerivative · entry 6 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,438 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 250 shares of Company stock on April 1, 2022 at prices ranging from $690.30 to $690.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.